Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials

References

• Khalil M, Vonderheide RH. Anti-CD40 agonist antibodies: preclinical and clinical experience. Update Cancer Ther 2007;2:61–65
   PubMedGoogle Scholar
• Lee JK, Seki N, Sayers TJ, et al. Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L. Cell Immunol 2005;235:145–152
   PubMed Web of Science ®Google Scholar
• Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002;297:2060–2063
   PubMed Web of Science ®Google Scholar
• Ma J, Usui Y, Kezuka T, et al. Costimulatory molecule expression on human uveal melanoma cells: functional analysis of CD40 and B7-H1. Exp Eye Res 2012;96:98–106
   PubMed Web of Science ®Google Scholar
• Luqman M, Klabunde S, Lin K, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008;112:711–720
   PubMed Web of Science ®Google Scholar
• Planken EV, Willemze R, Kluin-Nelemans JC. The role of the CD40 antigen on malignant B cells. Leuk Lymphoma 1996;22:229–235
   PubMed Web of Science ®Google Scholar
• Uckun FM, Gajl-Peczalska K, Myers DE, et al. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 1990;76:2449–2456
   PubMed Web of Science ®Google Scholar
• Funakoshi S, Longo DL, Beckwith M, et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994;83:2787–2794
   PubMed Web of Science ®Google Scholar
• Ghamande S, Hylander BL, Oflazoglu E, et al. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001;61:7556–7562
   PubMed Web of Science ®Google Scholar
• Kedar R, Sabag O, Licthenstein M, Lorberboum-Galski H. Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignancies. Cancer 2012;118:6089–6104
   PubMed Web of Science ®Google Scholar
• van KC, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000;67:2–17
   PubMed Web of Science ®Google Scholar
• Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478–480
   PubMed Web of Science ®Google Scholar
• Turner JG, Rakhmilevich AL, Burdelya L, et al. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol 2001;166:89–94
   PubMed Web of Science ®Google Scholar
• Ridge JP, Di RF, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998;393:474–478
   PubMed Web of Science ®Google Scholar
• Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480–483
   PubMed Web of Science ®Google Scholar
• Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5:780–787
   PubMed Web of Science ®Google Scholar
• Alexandroff AB, Jackson AM, Paterson T, et al. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 2000;37:515–526
   PubMed Web of Science ®Google Scholar
• Eliopoulos AG, Davies C, Knox PG, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000;20:5503–5515
   PubMed Web of Science ®Google Scholar
• Tong AW, Papayoti MH, Netto G, et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001;7:691–703
   PubMed Web of Science ®Google Scholar
• von LA, van der Bruggen P, Pahl HL, et al. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 1999;59:1287–1294
   PubMed Web of Science ®Google Scholar
• de Vos AF, Melief MJ, van RD, et al. Antagonist anti-human CD40 antibody inhibits germinal center formation in cynomolgus monkeys. Eur J Immunol 2004;34:3446–3455
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53:424–429
   PubMed Web of Science ®Google Scholar
• Tai YT, Li X, Tong X, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005;65:5898–5906
   PubMed Web of Science ®Google Scholar
• Advani R, Forero-Torres A, Furman RR, et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4371–4377
   PubMed Web of Science ®Google Scholar
• Jackaman C, Nelson DJ. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+-independent resolution of treated-tumors and CD4+-dependent systemic and memory responses. Cancer Immunol Immunother 2012;61:549–560
   PubMed Web of Science ®Google Scholar
• Fransen MF, Sluijter M, Morreau H, et al. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 2011;17:2270–2280
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007;25:876–883
   PubMed Web of Science ®Google Scholar
• Law CL, Gordon KA, Collier J, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005;65:8331–8338
   PubMed Web of Science ®Google Scholar
• Furman RR, Forero-Torres A, Shustov A, Drachman JG. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:228–235
   PubMed Web of Science ®Google Scholar
• Ruter J, Antonia SJ, Burris HA, et al. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther 2010;10:983–993
   PubMed Web of Science ®Google Scholar
• Lewis TS, McCormick RS, Emmerton K, et al. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clin Cancer Res 2011;17:4672–4681
   PubMed Web of Science ®Google Scholar
• Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612–1616
   PubMed Web of Science ®Google Scholar
• Beatty GL, Torigian DA, Chiorean EG, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 2013;19:6286–6295
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Burg JM, Mick R, et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013;2:e23033
   PubMed Web of Science ®Google Scholar
• Bensinger W, Maziarz RT, Jagannath S, et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol 2012;159:58–66
   PubMed Web of Science ®Google Scholar
• Van LS, Goyvaerts C, Maenhout S, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012;72:1661–1671
   PubMed Web of Science ®Google Scholar
• Met O, Wang M, Pedersen AE, et al. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett 2006;231:247–256
   PubMed Web of Science ®Google Scholar
• Murphy WJ, Welniak L, Back T, et al. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol 2003;170:2727–2733
   PubMed Web of Science ®Google Scholar
• Liu C, Lewis CM, Lou Y, et al. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother 2012;35:276–282
   PubMed Web of Science ®Google Scholar
• Busse D, de la Rosa M, Hobiger K, et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc Natl Acad Sci USA 2010;107:3058–3063
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003;9:269–277
   PubMed Web of Science ®Google Scholar
• Salcedo R, Hixon JA, Stauffer JK, et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol 2009;182:4328–4338
   Google Scholar
• Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003;63:4490–4496
   PubMed Web of Science ®Google Scholar
• Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006;12:693–698
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278–287
   PubMed Web of Science ®Google Scholar
• Vose J, Sneller V. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. Ann Oncol 2003;14:i17–i20
   PubMed Web of Science ®Google Scholar
• Reuben JM, Lee BN, Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006;106:2437–2444
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Dutcher JP, Anderson JE, et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 2001;19:3280–3287
   PubMed Web of Science ®Google Scholar
• Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007;13:1083–1088
   PubMed Web of Science ®Google Scholar
• Hussein M, Berenson JR, Niesvizky R, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010;95:845–848
   PubMed Web of Science ®Google Scholar
• Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003;10:1–13
   PubMed Web of Science ®Google Scholar
• Ahonen CL, Doxsee CL, McGurran SM, et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004;199:775–784
   PubMed Web of Science ®Google Scholar
• Welniak LA, Shorts L, Subleski J, et al. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects. Biol Blood Marrow Transplant 2004;10:534–539
   PubMed Web of Science ®Google Scholar
• Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999;5:774–779
   PubMed Web of Science ®Google Scholar
• Klein D, Barbe-Tuana F, Pugliese A, et al. A functional CD40 receptor is expressed in pancreatic beta cells. Diabetologia 2005;48:268–276
   PubMed Web of Science ®Google Scholar
• Vosters O, Beuneu C, Nagy N, et al. CD40 expression on human pancreatic duct cells: role in nuclear factor-kappa B activation and production of pro-inflammatory cytokines. Diabetologia 2004;47:660–668
   PubMed Web of Science ®Google Scholar
• Bell DJ, Wilson MW. Choroidal melanoma: natural history and management options. Cancer Control 2004;11:296–303
   PubMedGoogle Scholar
• Cowey CL. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma. Drug Des Devel Ther 2013; 7:519–527
   PubMed Web of Science ®Google Scholar
• Fisher B. Biological research in the evolution of cancer surgery: a personal perspective. Cancer Res 2008;68:10007–10020
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750–1757
   PubMed Web of Science ®Google Scholar
• Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996;347:1432–1438
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885–891
   PubMed Web of Science ®Google Scholar
• Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007;25:793–798
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088
   PubMed Web of Science ®Google Scholar
• Mato AR, Feldman T, Goy A. Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. Oncologist 2012;17:694–707
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690–697
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Vose J, Nademanee A, et al. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. Oncologist 2009;14:41–51
   PubMed Web of Science ®Google Scholar
• Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680–1685
   PubMed Web of Science ®Google Scholar
• Kapoor P, Ramakrishnan V, Rajkumar SV. Bortezomib combination therapy in multiple myeloma. Semin Hematol 2012;49:228–242
   PubMed Web of Science ®Google Scholar